Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Leukemia · Acute Lymphoblastic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Stanford University, Palo Alto, California, United States
Contact: Study coordinator (Michelle Fujimoto) · mfujimot@stanford.edu · 650-736-0539
Contact: Principal Investigator (Kara L Davis, DO)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Myelodysplastic Syndrome

Abroad (travel likely)RecruitingPHASE1

Duarte, United States

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE1

Seoul, South Korea

Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia

Survivor of Childhood Cancer · Insomnia · Acute Lymphoblastic Leukemia (ALL)

Abroad (travel likely)Recruiting

Memphis, United States

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

T-Cell Acute Lymphocytic Leukemia · Acute Lymphoblastic Leukemia, in Relapse · Refractory Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China · Shanghai, China